Cilgavimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Cilgavimab
- 2130
- azd 1061
- AZD-1061
- azd1061
- AZD1061
- AZD1061 (cell pool material)
- AZD1061 (clonal cell line material)
- azd1061 cell pool material
- cilgavimab
- Cilgavimab
- cilgavimab [INN]
- CILGAVIMAB [JAN]
- CILGAVIMAB [USAN]
- Cilgavimab [WHO-DD]
- cilgavimab inn
- cilgavimab jan
- cilgavimab usan
- cilgavimab who dd
- cov2 2130
- COV2-2130
- IMMUNOGLOBULIN G1 (248-THREONINE,249-METHIONINE,316-TYROSINE,318-THREONINE,320-GLUTAMIC ACID), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL AZD1061 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AZD1061 .KAPPA.-CHAIN, DIMER
- immunoglobulin g1 248 threonine 249 methionine 316 tyrosine 318 threonine 320 glutamic acid anti severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor binding domain human monoclonal azd1061 gamma 1 chain disulfide with human monoclonal azd1061 kappa chain dimer
- CAS registry numbers
- 2420563-99-9
- ChEMBL ID
- CHEMBL4650258
- RxNorm IDs (RxCUI)
- 2587306
- FDA ingredient codes (UNII)
- 1KUR4BN70F
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- cilgavimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Mechanism
- Spike glycoprotein blocker
- Action type
- Blocker
- Target
- Spike glycoprotein
- Protein identifier
- P0DTC2
Open Targets mechanisms
- Mechanism
- Spike glycoprotein blocker
- Action type
- Blocker
- Target
- Spike glycoprotein
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
Open Targets indications
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05166421
- NCT05321394
- NCT05375760
- NCT05438498
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 311 $ 311''''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 311 $ 311''
- Component
- Disulfide bridges
- Sequence
- 22-98 $ 22''-98'' $ 23'-94' $ 23'''-94''' $ 130'-199' $ 139'''-199''' $ 158-214 $ 159''-214'' $ 234-219' $ 234''-219''' $ 240-240'' $ 243-243'' $ 275-335 $ 275''-335'' $ 381-439 $ 381''-439''
Related records
Trials (4)
- A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
- Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
- Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
- Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants
In development for (1)
- COVID-19 Phase 3